There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT), Horizon Pharma Inc (HZNP) and Intec Pharma Ltd (NTEC) with bullish sentiments.
Sarepta Therapeutics (SRPT)
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Sarepta Therapeutics, with a price target of $178. The company’s shares opened today at $151.99.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.6% and a 50.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Scholar Rock Holding Corp.
Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $202.62, representing a 33.3% upside. In a report issued on February 12, Nomura also reiterated a Buy rating on the stock with a $205 price target.
See today’s analyst top recommended stocks >>
Horizon Pharma Inc (HZNP)
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Horizon Pharma Inc today and set a price target of $26. The company’s shares opened today at $22.14, close to its 52-week high of $24.03.
Chen said:
“. Post a 4Q18 beat, we are reiterating our OW rating and raising our 12-month PT to $26 from $23. The increase in our PT is driven by upwards earnings revisions. We use a blend of DCF and EV/EBITDA analysis to arrive at our new PT. We also continue to expect upside to FactSet estimates for HZNP’s orphan as well as rheumatology businesses and multiple expansion to drive the stock higher.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.0% and a 41.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Horizon Pharma Inc with a $24.50 average price target.
Intec Pharma Ltd (NTEC)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Intec Pharma Ltd today and set a price target of $12. The company’s shares opened today at $8.75, close to its 52-week high of $9.25.
McCarthy observed:
“Intec reported YE18 with a net loss of ($43.5M) and ended the period with $40.6M in cash, runway into 4Q19 and importantly in our view, through the pivotal phase 3 data for Accordion Pill carbidopa/levodopa (AP-CD/LD) in Parkinson’s disease which is expected in mid-2019. We are also watching the progression with the Accordion Pill -Tetrahydrocannabinol (AP – THC) in pain as well as the collaboration with Novartis (NVS – NR) (see below).”
According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -1.2% and a 33.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Aridis Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.
Intec Pharma Ltd has an analyst consensus of Strong Buy, with a price target consensus of $14.50, implying a 65.7% upside from current levels. In a report issued on February 19, Ladenburg also maintained a Buy rating on the stock with a $15 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
